Monitor the BioLife special meeting vote and HSR waiting period expiration (scheduled Sept 3, 2026). The fixed exchange ratio means RGEN's stock price movement directly impacts the deal's value for BLFS holders. Watch for any competing bids or regulatory delays that could alter the timeline or terms.
Price Chart
Executive Summary
Repligen filed an S-4 registration statement for its acquisition of BioLife Solutions (BLFS). BioLife stockholders will receive $11.25 cash and 0.1442 Repligen shares per BLFS share, implying a value of ~$37.37 based on RGEN's August 21 close. The deal is expected to close in Q4 2026, subject to BioLife stockholder approval, HSR clearance, and other conditions. The fixed exchange ratio means the stock consideration value fluctuates with RGEN's price, creating uncertainty for BLFS holders voting on the deal.
Key Facts
- Repligen is acquiring BioLife Solutions via a two-step merger for $11.25 cash + 0.1442 RGEN shares per BLFS share.
- The implied value per BLFS share was ~$37.37 as of August 21, 2026, based on RGEN's $181.13 close.
- BioLife stockholders must approve the merger; a special meeting is scheduled for [], 2026.
- The deal is expected to close in Q4 2026, subject to HSR clearance and other conditions.
- BioLife's financial advisor Centerview Partners opined the consideration is fair; BioLife will pay Centerview ~$25M total, with ~$24M contingent on closing.
- If terminated under certain conditions, BioLife must pay Repligen a $59M termination fee.
- The exchange ratio is fixed and will not adjust for market price changes, creating risk for BLFS holders.
Financial Impact
BioLife stockholders receive $11.25 cash + 0.1442 RGEN shares per BLFS share; implied value ~$37.37 as of Aug 21, 2026
Risk Factors
- BioLife stockholders may not approve the merger, blocking the deal.
- Regulatory approvals (HSR, foreign antitrust) could be delayed or impose conditions.
- The fixed exchange ratio exposes BLFS holders to RGEN stock price declines before closing.
- Integration risks could affect Repligen's post-merger financial performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4 Filing (Primary) | 0001193125-26-363970 |
| Document: 0001193125-26-363970-index.html | 0001193125-26-363970 |
| Document: 0001193125-26-363970.txt | 0001193125-26-363970 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | S-4 | $181.69 $184.53 | ▲ +1.56% | ▲ +0.59% | $185.41 (+2.05%) |
Jul 28, 2026 9w ago | 8-K | $145.34 $181.69 | ▲ +25.01% | ▲ +21.63% | $185.41 (+27.57%) |
Jul 22, 2026 10w ago | 425 / 8-K | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $185.41 (+32.35%) |
Jul 22, 2026 10w ago | Press Release | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $185.41 (+32.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $130.59 $144.24 | ▲ +10.45% | ▲ +8.67% | $185.41 (+41.98%) |
May 5, 2026 21w ago | 8-K | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $185.41 (+47.61%) |
May 5, 2026 21w ago | Press Release | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $185.41 (+47.61%) |
Apr 22, 2026 23w ago | Press Release | $124.40 $108.52 | ▼ −12.77% | ▼ −15.93% | $185.41 (+49.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access